Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib
Inhibition of metastasis of head and neck squamous cell carcinoma (HNSCC) is one of the most important challenges in cancer treatment. Src, a non-receptor tyrosine kinase, has been implicated as a key promoter... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - June 20, 2018 Category: Hematology Authors: Liwei Lang, Chloe Shay, Yuanping Xiong, Parth Thakkar, Ron Chemmalakuzhy, Xuli Wang and Yong Teng Tags: Research Source Type: research

Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy
Bcr-Abl inhibitors paved the way of targeted therapy epoch. Imatinib was the first tyrosine kinase inhibitor to be discovered with high specificity for Bcr-Abl protein resulting from t(9, 22)-derived Philadelp... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - June 20, 2018 Category: Hematology Authors: Federico Rossari, Filippo Minutolo and Enrico Orciuolo Tags: Review Source Type: research

NF- κB signaling and its relevance to the treatment of mantle cell lymphoma
Mantle cell lymphoma is an aggressive subtype of non-Hodgkin B cell lymphoma that is characterized by a poor prognosis determined by Ki67 and Mantle Cell International Prognostic Index scores, but it is becomi... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - June 15, 2018 Category: Hematology Authors: Swathi Balaji, Makhdum Ahmed, Elizabeth Lorence, Fangfang Yan, Krystle Nomie and Michael Wang Tags: Review Source Type: research

Exosomes released by hepatocarcinoma cells endow adipocytes with tumor-promoting properties
The initiation and progression of hepatocellular carcinoma (HCC) are largely dependent on its local microenvironment. Adipocytes are an important component of hepatic microenvironment in nonalcoholic fatty liv... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - June 14, 2018 Category: Hematology Authors: Shihua Wang, Meiqian Xu, Xiaoxia Li, Xiaodong Su, Xian Xiao, Armand Keating and Robert Chunhua Zhao Tags: Research Source Type: research

Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
The original article contains several small errors. The errors& concurrent corrections are listed below [1]: (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - June 13, 2018 Category: Hematology Authors: D. Porter, N. Frey, P. A. Wood, Y. Weng and S. A. Grupp Tags: Correction Source Type: research

Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study
Ibrutinib is an oral irreversible inhibitor of Bruton ’s tyrosine kinase, indicated for the treatment of chronic lymphocytic leukaemia. The drug is generally well tolerated; however, not infrequent side effects... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - June 11, 2018 Category: Hematology Authors: Gianluigi Reda, Bruno Fattizzo, Ramona Cassin, Veronica Mattiello, Tatiana Tonella, Diana Giannarelli, Ferdinando Massari and Agostino Cortelezzi Tags: Letter to the Editor Source Type: research

Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
Endocrine therapy has historically formed the basis of treatment of metastatic hormone receptor-positive breast cancer. The development of endocrine resistance has led to the development of newer endocrine dru... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - June 11, 2018 Category: Hematology Authors: Anishka D ’Souza, Darcy Spicer and Janice Lu Tags: Review Source Type: research

Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers
Unlike many conventional cancers with preferential patterns of oncogenic genetic alterations, TRK fusions resulting from NTRK1/2/3 genetic alterations drive oncogenic transformations in more than 20 different ... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - June 7, 2018 Category: Hematology Authors: Yu Chen and Ping Chi Tags: Research highlight Source Type: research

MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis
We analyzed clinical associations of MET alterations in the plasma of patients with diverse malignancies. (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - June 4, 2018 Category: Hematology Authors: Sadakatsu Ikeda, Maria Schwaederle, Mandakini Mohindra, Denis L. Fontes Jardim and Razelle Kurzrock Tags: Research Source Type: research

A cytoplasmic long noncoding RNA LINC00470 as a new AKT activator to mediate glioblastoma cell autophagy
Despite the overwhelming number of investigations on AKT, little is known about lncRNA on AKT regulation, especially in GBM cells. (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - June 4, 2018 Category: Hematology Authors: Changhong Liu, Yan Zhang, Xiaoling She, Li Fan, Peiyao Li, Jianbo Feng, Haijuan Fu, Qing Liu, Qiang Liu, Chunhua Zhao, Yingnan Sun and Minghua Wu Tags: Research Source Type: research

The role of HGF-MET pathway and CCDC66 cirRNA expression in EGFR resistance and epithelial-to-mesenchymal transition of lung adenocarcinoma cells
Epithelial-to-mesenchymal transition (EMT) has, in recent years, emerged as an important tumor cell behavior associated with high metastatic potential and drug resistance. Interestingly, protein SUMOylation an... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - May 31, 2018 Category: Hematology Authors: Nithila A. Joseph, Shiow-Her Chiou, Zoe Lung, Cheng-Lin Yang, Tze-Yi Lin, Hui-Wen Chang, H. Sunny Sun, Sachin Kumar Gupta, Laising Yen, Shulhn-Der Wang and Kuan-Chih Chow Tags: Research Source Type: research

Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why
It is well known that chemotherapy can cure only some cancers in advanced stage, mostly those with an intact p53 pathway. Hematological cancers such as lymphoma and certain forms of leukemia are paradigmatic e... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - May 31, 2018 Category: Hematology Authors: Enrico Derenzini, Alessandra Rossi and Davide Trer é Tags: Review Source Type: research

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
Binding of insulin-like growth factor-I (IGF-1) to its receptor (IGF-1R) initiates downstream signals that activate PI3K/Akt/mTOR and MEK/Erk pathways, which stimulate cancer cell proliferation and induce drug... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - May 30, 2018 Category: Hematology Authors: Reham Abdel-Wahab, Gauri R. Varadhachary, Priya R. Bhosale, Xuemei Wang, David R. Fogelman, Rachna T. Shroff, Michael J. Overman, Robert A. Wolff and Milind Javle Tags: Research Source Type: research

STARD13-correlated ceRNA network-directed inhibition on YAP/TAZ activity suppresses stemness of breast cancer via co-regulating Hippo and Rho-GTPase/F-actin signaling
Targeting cancer stem cells is critical for suppressing cancer progression and recurrence. Finding novel markers or related pathways could help eradicate or diagnose cancer in clinic. (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - May 30, 2018 Category: Hematology Authors: Lufeng Zheng, Chenxi Xiang, Xiaoman Li, Qianqian Guo, Lanlan Gao, Haiwei Ni, Yufeng Xia and Tao Xi Tags: Research Source Type: research

Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways
The increasing genomic complexity of acute myeloid leukemia (AML), the most common form of acute leukemia, poses a major challenge to its therapy. To identify potent therapeutic targets with the ability to blo... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - May 30, 2018 Category: Hematology Authors: Xiaolan Lian, Yu-Min Lin, Shingo Kozono, Megan K. Herbert, Xin Li, Xiaohong Yuan, Jiangrui Guo, Yafei Guo, Min Tang, Jia Lin, Yiping Huang, Bixin Wang, Chenxi Qiu, Cheng-Yu Tsai, Jane Xie, Ziang Jeff Cao & hellip; Tags: Research Source Type: research

miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3/Bcl2 signaling pathway
Chemoresistance to temozolomide (TMZ) is a major challenge in the treatment of glioblastoma (GBM). We previously found that miR-519a functions as a tumor suppressor in glioma by targeting the signal transducer an... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - May 29, 2018 Category: Hematology Authors: Hong Li, Lei Chen, Jun-jie Li, Qiang Zhou, Annie Huang, Wei-wen Liu, Ke Wang, Liang Gao, Song-tao Qi and Yun-tao Lu Tags: Research Source Type: research

Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
The international, phase 3 COMPARZ study demonstrated that pazopanib and sunitinib have comparable efficacy as first-line therapy in patients with advanced renal cell carcinoma, but that safety and quality-of-... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - May 22, 2018 Category: Hematology Authors: Jun Guo, Jie Jin, Mototsugu Oya, Hirotsugu Uemura, Shunji Takahashi, Katsunori Tatsugami, Sun Young Rha, Jae-Lyun Lee, Jinsoo Chung, Ho Yeong Lim, Hsi Chin Wu, Yen Hwa Chang, Arun Azad, Ian D. Davis, Marlene J. Carrasco-Alfonso, Bhupinder Nanua & hellip; Tags: Research Source Type: research

Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential
Multiple myeloma is the second most frequent hematological malignancy in the western world and remains incurable, predominantly due to acquired drug resistance and disease relapse. The highly conserved Wnt sig... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - May 18, 2018 Category: Hematology Authors: Ingrid Spaan, Reinier A. Raymakers, Anja van de Stolpe and Victor Peperzak Tags: Review Source Type: research

Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma
Metastatic melanoma is an aggressive skin cancer with a poor prognosis. Current treatment strategies for high-stage melanoma are based around the use of immunotherapy with immune checkpoint inhibitors such as ... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - May 18, 2018 Category: Hematology Authors: Carmela De Santo, Paul Cheng, Andrew Beggs, Sharon Egan, Alberto Bessudo and Francis Mussai Tags: Case report Source Type: research

Myeloma-derived macrophage inhibitory factor regulates bone marrow stromal cell-derived IL-6 via c-MYC
Multiple myeloma (MM) remains an incurable malignancy despite the recent advancements in its treatment. The protective effects of the niche in which it develops has been well documented; however, little has be... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - May 16, 2018 Category: Hematology Authors: Rachel E. Piddock, Christopher R. Marlein, Amina Abdul-Aziz, Manar S. Shafat, Martin J. Auger, Kristian M. Bowles and Stuart A. Rushworth Tags: Letter to the Editor Source Type: research

BCL-2 as therapeutic target for hematological malignancies
Disruption of the physiologic balance between cell proliferation and cell death is an important step of cancer development. Increased resistance to apoptosis is a key oncogenic mechanism in several hematologic... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - May 11, 2018 Category: Hematology Authors: Guilherme Fleury Perini, Glaciano Nogueira Ribeiro, Jorge Vaz Pinto Neto, Laura Tojeiro Campos and Nelson Hamerschlak Tags: Review Source Type: research

The biology and role of CD44 in cancer progression: therapeutic implications
CD44, a non-kinase transmembrane glycoprotein, is overexpressed in several cell types including cancer stem cells and frequently shows alternative spliced variants that are thought to play a role in cancer dev... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - May 10, 2018 Category: Hematology Authors: Chen Chen, Shujie Zhao, Anand Karnad and James W. Freeman Tags: Review Source Type: research

MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches
The deeper understanding of non-coding RNAs has recently changed the dogma of molecular biology assuming protein-coding genes as unique functional biological effectors, while non-coding genes as junk material ... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - May 8, 2018 Category: Hematology Authors: Nicola Amodio, Lavinia Raimondi, Giada Juli, Maria Angelica Stamato, Daniele Caracciolo, Pierosandro Tagliaferri and Pierfrancesco Tassone Tags: Review Source Type: research

Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements
Promotor hypermethylation of CpG islands is common in B cell precursor acute lymphoblastic leukemia (BCP-ALL) with mixed lineage leukemia (MLL) gene rearrangements. Hypomethylating agents (HMA) such as azaciti... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - May 4, 2018 Category: Hematology Authors: C. Roolf, A. Richter, C. Konkolefski, G. Knuebel, A. Sekora, S. Krohn, J. Stenzel, B. J. Krause, B. Vollmar, H. Murua Escobar and C. Junghanss Tags: Research Source Type: research

First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a highly aggressive hematological malignancy with extremely poor outcome. The median overall survival for adult patients is 9 –13 months. Pediatric patien... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - May 2, 2018 Category: Hematology Authors: Weili Sun, Huaying Liu, Young Kim, Nicole Karras, Anna Pawlowska, Debbie Toomey, Wade Kyono, Paul Gaynon, Joseph Rosenthal and Anthony Stein Tags: Case report Source Type: research

Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells
Chimeric antigen receptor-engineered T (CAR-T) cells have extraordinary effect in treating lymphoblastic leukemia. However, treatment of acute myeloid leukemia (AML) using CAR-T cells remains limited to date. ... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - May 2, 2018 Category: Hematology Authors: Ying Wang, Yingxi Xu, Saisai Li, Jia Liu, Yanyan Xing, Haiyan Xing, Zheng Tian, Kejing Tang, Qing Rao, Min Wang and Jianxiang Wang Tags: Research Source Type: research

Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery
Heat shock protein 90 (Hsp90) is a critical molecular chaperone protein that regulates the folding, maturation, and stability of a wide variety of proteins. In recent years, the development of Hsp90-directed i... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - April 27, 2018 Category: Hematology Authors: Ting Li, Hu-Lin Jiang, Yun-Guang Tong and Jin-Jian Lu Tags: Review Source Type: research

Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma
CD30 and programmed cell death protein 1 (PD-1) are two ideal therapeutic targets in classical Hodgkin lymphoma (cHL). The CD30 antibody-drug conjugate (ADC) brentuximab vedotin and the PD-1 antibodies nivolum... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - April 23, 2018 Category: Hematology Authors: Yucai Wang, Grzegorz S. Nowakowski, Michael L. Wang and Stephen M. Ansell Tags: Review Source Type: research

miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy
Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes the first and rate-limiting step in converting tryptophan to kynurenine. Chimeric antigen receptor (CAR) T cells are T cells with recombinant receptors targeting ... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - April 23, 2018 Category: Hematology Authors: Qian Huang, Jiajia Xia, Lei Wang, Xu Wang, Xiaodong Ma, Qipan Deng, Yong Lu, Munish Kumar, Zhiyuan Zhou, Ling Li, Zhaoyang Zeng, Ken H. Young, Qing Yi, Mingzhi Zhang and Yong Li Tags: Research Source Type: research

Correction to: miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a
The original article [1] contains an error in Fig. 5a whereby the Western blot bands representing CyclinD1 have mistakenly been duplicated over the Western blot bands intended to represent SGK. (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - April 18, 2018 Category: Hematology Authors: Man-Qing Cao, A-Bin You, Xiao-Dong Zhu, Wei Zhang, Yuan-Yuan Zhang, Shi-Zhe Zhang, Kei-wei Zhang, Hao Cai, Wen-Kai Shi, Xiao-Long Li, Kang-Shuai Li, Dong-Mei Gao, De-Ning Ma, Bo-Gen Ye, Cheng-Hao Wang, Cheng-Dong Qin & hellip; Tags: Correction Source Type: research

Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT
Acute myeloid leukemia (AML) is both more common and with more biologically aggressive phenotype in the elderly. Allogenic stem cell transplantation (allo-SCT) is the best treatment option in fit patients. Eit... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - April 16, 2018 Category: Hematology Authors: Nicole Santoro, Myriam Labopin, Federica Giannotti, Gerard Ehninger, Dietger Niederwieser, Arne Brecht, Matthias Stelljes, Nicolaus Kr öger, Herman Einsele, Matthias Eder, Michael Hallek, Bertram Glass, Jürgen Finke, Fabio Ciceri, Mohamad Mohty, Annalis Tags: Research Source Type: research

Exosomal miRNAs in hepatocellular carcinoma development and clinical responses
Hepatocellular carcinoma remains the sixth most lethal malignancy in the world. While HCC is often diagnosed via current biomarkers at a late stage, early detection of HCC has proven to be very difficult. Rece... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - April 11, 2018 Category: Hematology Authors: Shuangshuang Li, Jiping Yao, Mingjie Xie, Yanning Liu and Min Zheng Tags: Review Source Type: research

DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis
C-X-C motif ligand 8 (CXCL8), known as a proinflammatory chemokine, exerts multiple effects on the proliferation, invasion, and migration of tumor cells via the autocrine or paracrine manner. Conversely, the h... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - April 10, 2018 Category: Hematology Authors: Qian Liu, Anping Li, Shengnan Yu, Shuang Qin, Na Han, Richard G. Pestell, Xinwei Han and Kongming Wu Tags: Research Source Type: research

Expression levels of long non-coding RNAs are prognostic for AML outcome
Long non-coding RNA (lncRNA) expression has been implicated in a range of molecular mechanisms that are central in cancer. However, lncRNA expression has not yet been comprehensively characterized in acute mye... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - April 7, 2018 Category: Hematology Authors: Arvind Singh Mer, Johan Lindberg, Christer Nilsson, Daniel Klevebring, Mei Wang, Henrik Gr önberg, Soren Lehmann and Mattias Rantalainen Tags: Research Source Type: research

Correction to: Role of protein kinases CK1 α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways
The original article [1] contains an inadvertent error in the following sentence in the Abstract regarding the erroneous description of Ser/Thr kinases as ‘phylogenetically related’: (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - April 5, 2018 Category: Hematology Authors: Sabrina Manni, Marilena Carrino and Francesco Piazza Tags: Correction Source Type: research

Increased B3GALNT2 in hepatocellular carcinoma promotes macrophage recruitment via reducing acetoacetate secretion and elevating MIF activity
Hepatocellular carcinoma (HCC) ranks as the sixth most prevalent cancer and the third leading cause of tumor-related death, so it is urgently needed to discover efficient markers and targets for therapy. β-1,3-N-... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - April 4, 2018 Category: Hematology Authors: Tianxiao Yang, Yilin Wang, Wenjuan Dai, Xixi Zheng, Jing Wang, Shushu Song, Lan Fang, Jiangfan Zhou, Weicheng Wu and Jianxin Gu Tags: Research Source Type: research

Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
In ASPIRE, carfilzomib, lenalidomide, and dexamethasone (KRd) significantly improved progression-free survival (PFS) and response rates versus lenalidomide and dexamethasone (Rd) in patients with relapsed mult... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - April 4, 2018 Category: Hematology Authors: Meletios Dimopoulos, Michael Wang, Vladimir Maisnar, Jiri Minarik, William Bensinger, Maria-Victoria Mateos, Mihaela Obreja, Julie Blaedel and Philippe Moreau Tags: Research Source Type: research

Gut microbiome modulates efficacy of immune checkpoint inhibitors
Immune checkpoint inhibitors (ICIs) therapy is a novel strategy for cancer treatments in recent years. However, it was observed that most patients treated with ICIs could not get benefit from the therapy, whic... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - March 27, 2018 Category: Hematology Authors: Ming Yi, Shengnan Yu, Shuang Qin, Qian Liu, Hanxiao Xu, Weiheng Zhao, Qian Chu and Kongming Wu Tags: Review Source Type: research

Multiple functions of m6A RNA methylation in cancer
First identified in 1974, m6A RNA methylation, which serves as a predominant internal modification of RNA in higher eukaryotes, has gained prodigious interest in recent years. Modifications of m6A are dynamic and... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - March 27, 2018 Category: Hematology Authors: Yutian Pan, Pei Ma, Yu Liu, Wei Li and Yongqian Shu Tags: Review Source Type: research

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Even with recent advances in therapy regimen, multiple myeloma patients commonly develop drug resistance and relapse. The relevance of targeting the PD-1/PD-L1 axis has been demonstrated in pre-clinical models... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - March 27, 2018 Category: Hematology Authors: Rosemarie Tremblay-LeMay, Nasrin Rastgoo and Hong Chang Tags: Review Source Type: research

MiR-16 regulates the pro-tumorigenic potential of lung fibroblasts through the inhibition of HGF production in an FGFR-1- and MEK1-dependent manner
Fibroblasts are crucial mediators of tumor-stroma cross-talk through synthesis and remodeling of the extracellular matrix and production of multiple soluble factors. Nonetheless, little is still known about sp... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - March 20, 2018 Category: Hematology Authors: Francesca Andriani, Maria Teresa Majorini, Miguel Mano, Elena Landoni, Rosalba Miceli, Federica Facchinetti, Mavis Mensah, Enrico Fontanella, Matteo Dugo, Mauro Giacca, Ugo Pastorino, Gabriella Sozzi, Domenico Delia, Luca Roz and Daniele Lecis Tags: Research Source Type: research

The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma
Mantle cell lymphoma (MCL) is an incurable B cell-derived malignant tumor with a median overall survival of 4 –5 years. Mer tyrosine kinase (MerTK) has been reported to be aberrantly expressed in leukemia, mela... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - March 20, 2018 Category: Hematology Authors: Cunzhen Shi, Xiangqun Li, Xiaogan Wang, Ning Ding, Lingyan Ping, Yunfei Shi, Lan Mi, Yumei Lai, Yuqin Song and Jun Zhu Tags: Research Source Type: research

Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide
Chimeric antigen receptors (CARs) presented on T cell surfaces enable redirection of T cell specificity, which has enormous promise in antitumor therapy. However, excessive activity and poor control over such ... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - March 20, 2018 Category: Hematology Authors: Erhao Zhang, Jieyi Gu, Jianpeng Xue, Chenyu Lin, Chen Liu, Mengwei Li, Jingchao Hao, Sarra Setrerrahmane, Xiaowei Chi, Weiyan Qi, Jialiang Hu and Hanmei Xu Tags: Research Source Type: research

CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies
The prognosis of adults with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) remains dismal even at this day and age. With salvage chemotherapy, only 29% (range 18 to 44%) of the patients with R/R... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - March 15, 2018 Category: Hematology Authors: Li-Na Zhang, Yongping Song and Delong Liu Tags: Research highlight Source Type: research

Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT
Experience using post-transplant cyclophosphamide (PT-Cy) as graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation (HSCT) from matched sibling donors (MSD) or unrelated donors (U... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - March 15, 2018 Category: Hematology Authors: Annalisa Ruggeri, Myriam Labopin, Andrea Bacigalupo, Boris Afanasyev, Jan J. Cornelissen, Ahmet Elmaagacli, Maija It älä-Remes, Didier Blaise, Ellen Meijer, Yener Koc, Noel Milpied, Harry C. Schouten, Nicolaus Kroeger, Mohamad Mohty and Arnon Nagler Tags: Research Source Type: research

Next generation of immune checkpoint therapy in cancer: new developments and challenges
Immune checkpoints consist of inhibitory and stimulatory pathways that maintain self-tolerance and assist with immune response. In cancer, immune checkpoint pathways are often activated to inhibit the nascent ... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - March 15, 2018 Category: Hematology Authors: Julian A. Marin-Acevedo, Bhagirathbhai Dholaria, Aixa E. Soyano, Keith L. Knutson, Saranya Chumsri and Yanyan Lou Tags: Review Source Type: research

Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
Myelofibrosis (MF) is a life-shortening complication of myeloproliferative neoplasms associated with ineffective hematopoiesis, splenomegaly, and progressive bone marrow (BM) fibrosis. The oral Janus kinase (J... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - March 15, 2018 Category: Hematology Authors: Hans Michael Kvasnicka, J ürgen Thiele, Carlos E. Bueso-Ramos, William Sun, Jorge Cortes, Hagop M. Kantarjian and Srdan Verstovsek Tags: Research Source Type: research

Correction to: The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma
The original article [1] contained an error whereby Fig. 4 displayed incorrect magnification scales. (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - March 14, 2018 Category: Hematology Authors: C. Festuccia, A. Mancini, A. Colapietro, G. L. Gravina, F. Vitale, F. Marampon, S. Delle Monache, S. Pompili, L. Cristiano, A. Vetuschi, V. Tombolini, Y. Chen and T. Mehrling Tags: Correction Source Type: research

Correction to: PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse
The original article [1] contained an error in Table 1 whereby the ‘Positive’ column in the ‘PD-L1’ Tumor type group of columns was mistakenly included at the beginning of the ‘PD-L2’ Tumor type group of columns. (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - March 12, 2018 Category: Hematology Authors: Bingxin Zheng, Tingting Ren, Yi Huang, Kunkun Sun, Shidong Wang, Xing Bao, Kuisheng Liu and Wei Guo Tags: Correction Source Type: research

A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/ β-catenin pathways for treatment of AML with high PRL-3 phosphatase
Protein tyrosine phosphatase of regenerating liver 3 (PRL-3) is overexpressed in a subset of AML patients with inferior prognosis, representing an attractive therapeutic target. However, due to relatively shal... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - March 7, 2018 Category: Hematology Authors: Jianbiao Zhou, Sabrina Hui-Min Toh, Zit-Liang Chan, Jessie Yiying Quah, Jing-Yuan Chooi, Tuan Zea Tan, Phyllis S. Y. Chong, Qi Zeng and Wee-Joo Chng Tags: Research Source Type: research